These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29896665)

  • 1. Antiviral Drugs Against Alphaherpesvirus.
    Shiraki K
    Adv Exp Med Biol; 2018; 1045():103-122. PubMed ID: 29896665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
    Shiraki K
    Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
    Shiraki K; Yasumoto S; Toyama N; Fukuda H
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment.
    Shiraki K; Takemoto M; Daikoku T
    Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1415-1425. PubMed ID: 33853490
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antiviral resistance of herpes simplex virus and varicella-zoster virus].
    Daikoku T; Shiraki K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():480-6. PubMed ID: 17455667
    [No Abstract]   [Full Text] [Related]  

  • 6. Famciclovir/penciclovir.
    Sacks SL; Wilson B
    Adv Exp Med Biol; 1999; 458():135-47. PubMed ID: 10549386
    [No Abstract]   [Full Text] [Related]  

  • 7. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
    Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
    Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir.
    Shiraki K; Tan L; Daikoku T; Takemoto M; Sato N; Yoshida Y
    Antiviral Res; 2020 Aug; 180():104829. PubMed ID: 32569704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs in development for herpes simplex and varicella zoster virus.
    Birkmann A; Zimmermann H
    Clin Pharmacol Ther; 2017 Jul; 102(1):30-32. PubMed ID: 28160282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections.
    Wu JJ; Brentjens MH; Torres G; Yeung-Yue K; Lee P; Tyring SK
    J Cutan Med Surg; 2003; 7(5):372-81. PubMed ID: 14505192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study.
    Kawashima M; Nemoto O; Honda M; Watanabe D; Nakayama J; Imafuku S; Kato T; Katsuramaki T;
    J Dermatol; 2017 Nov; 44(11):1219-1227. PubMed ID: 28681394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].
    Morfin F; Frobert E; Thouvenot D
    Ann Biol Clin (Paris); 2003; 61(1):33-40. PubMed ID: 12604384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
    Pacreau ML; Bomme O; Burrel S; Boutolleau D
    Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral therapy of herpes simplex and varicella-zoster virus infections.
    Wutzler P
    Intervirology; 1997; 40(5-6):343-56. PubMed ID: 9675639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
    Biswas S; Sukla S; Field HJ
    Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral agents for herpes simplex virus.
    Vere Hodge RA; Field HJ
    Adv Pharmacol; 2013; 67():1-38. PubMed ID: 23885997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management.
    Piret J; Boivin G
    Curr Opin Infect Dis; 2016 Dec; 29(6):654-662. PubMed ID: 27306564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Helicase-primase as a target of new therapies for herpes simplex virus infections.
    James SH; Larson KB; Acosta EP; Prichard MN
    Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from Gilead Sciences Inc.
    Gege C; Kleymann G
    Expert Opin Ther Pat; 2024 Oct; 34(10):863-872. PubMed ID: 39262042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.